Envoy Medical (NASDAQ:COCH) Raised to Sell at Wall Street Zen

Envoy Medical (NASDAQ:COCH) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Envoy Medical in a research note on Thursday, October 30th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Envoy Medical presently has a consensus rating of “Hold” and a consensus target price of $9.50.

Envoy Medical Stock Performance

NASDAQ:COCH opened at $0.70 on Friday. The stock’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $1.31. Envoy Medical has a 52-week low of $0.70 and a 52-week high of $2.32. The company has a market cap of $18.03 million, a price-to-earnings ratio of -0.49 and a beta of 2.09.

Institutional Trading of Envoy Medical

A hedge fund recently bought a new stake in Envoy Medical stock. NorthRock Partners LLC purchased a new position in Envoy Medical, Inc. (NASDAQ:COCH) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 10,290,049 shares of the company’s stock, valued at approximately $14,612,000. NorthRock Partners LLC owned about 48.25% of Envoy Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 8.59% of the company’s stock.

About Envoy Medical

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.